Liming Wang
50Patents
6h-index
38Co-inventors
72Inventor score
Filing activity: Aug 29, 2000 → Jan 19, 2022
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US6313107A | Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI | Chemistry; Metallurgy | 27 | Expired |
| US6495552B2 | Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI | Chemistry; Metallurgy | 14 | Expired |
| US6380256B1 | Compounds having activity as inhibitors of cytochrome P450RAI | Chemistry; Metallurgy | 13 | Expired |
| US6369261B1 | Compounds having activity as inhibitors of cytochrome P450RAI | Chemistry; Metallurgy | 13 | Expired |
| US6387892B1 | Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI | Chemistry; Metallurgy | 12 | Expired |
| US7226951B2 | Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same | Chemistry; Metallurgy | 7 | Expired |
| US6855512B2 | Methods for identifying inhibitors of cytochrome P450RAI | Chemistry; Metallurgy | 6 | Expired |
| US6387951B1 | Compounds having activity as inhibitors of cytochrome P450RAI | Chemistry; Metallurgy | 5 | Expired |
| US8653123B2 | Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating retinal diseases | Chemistry; Metallurgy | 3 | Active |
| US7468391B2 | Methods for treating retinoid responsive disorders using selective inhibitors of CYP26A and CYP26B | Human Necessities | 3 | Active |
| US9040532B2 | Alpha adrenergic receptor modulators | Chemistry; Metallurgy | 3 | Active |
| US8853251B2 | Ester pro-drugs of [3-(1-(1H-imidazol-4-YL)ethyl)-2-methylphenyl] methanol for treating retinal diseases | Chemistry; Metallurgy | 3 | Active |
| US6603019B2 | 1-imidazolyl substituted tetrahydronaphthalene derivatives as inhibitors of eytochrome P450RAI | Chemistry; Metallurgy | 3 | Expired |
| US8492557B2 | Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol | Chemistry; Metallurgy | 3 | Active |
| US8492422B2 | Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating skin diseases and conditions | Chemistry; Metallurgy | 3 | Active |
| US9402913B2 | Cyclosporine A steroid conjugates | Chemistry; Metallurgy | 2 | Active |
| US9402912B2 | Antibiotic conjugates directly linked with steroid drugs | Chemistry; Metallurgy | 2 | Active |
| US7928081B2 | Combined use of PRAME inhibitors and HDAC inhibitors | Chemistry; Metallurgy | 1 | Expired |
| US8518932B2 | Oxime azetidine derivatives as sphingosine 1-phosphate (S1P) receptor modulators | Human Necessities | 1 | Active |
| US6740676B2 | 4-[(8-ETHYNYL, 8-VINYL OR 8-ETHYNYL-METHYL)-6-CHROMANOYL]-BENZOIC AND 2-[4-[(8-ETHYNYL, 8-VINYL OR 8-ETHYNYL-METHYL)-6-CHROMANOYL]-PHENYL]-ACETIC ACID, THEIR ESTERS AND SALTS HAVING CYTOCHROME P450RAI INHIBITORY ACTIVITY | Human Necessities | 1 | Expired |
| US8501796B2 | Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for lowering intraocular pressure | Chemistry; Metallurgy | 1 | Active |
| US8969544B2 | Combined use of PRAME inhibitors and HDAC inhibitors | Chemistry; Metallurgy | 1 | Active |
| US8623856B2 | Phenoxy-azetidine derivatives as sphingosine 1-phosphate (S1P) receptor modulators | Chemistry; Metallurgy | 1 | Active |
| US8399492B2 | Pyridine derivatives as sphingosine 1-phosphate (S1P) receptor modulators | Chemistry; Metallurgy | 0 | Active |
| US9199989B2 | N—(imidazolidin-2-ylidene)quinoline derivatives as modulators of alpha 2 adrenergic receptors | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.